Understanding Angioplasty by the Chocolate PTA Balloon Catheter Compared to Conventional PTA Balloons Via OCT Imaging

Infrainguinal Peripheral Arterial Disease Clinical Trial

Official title:

Understanding the Mechanism of Peripheral Arterial Balloon Angioplasty by the Chocolate PTA Balloon Catheter Compared to Conventional PTA Balloons Via OCT Imaging

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02237066
• Other study ID #: Chocolate OCT
• Status: Withdrawn
• Phase: N/A
• First received: September 3, 2014
• Last updated: March 17, 2015
• Start date: September 2014
• Est. completion date: March 2015

Study information

• Verified date: March 2015
• Source: TriReme Medical, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: The University Hospitals Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the Chocolate PTA Balloon to standard Percutaneous Transluminal Angioplasty (PTA) catheters. The investigators will use Optical Coherence Tomography (OCT) and Quantitative Vascular Angiography to evaluate the acute vascular response of vessels treated with the Chocolate Balloon to a standard balloon catheter, with the primary endpoint being luminal gain assessed by OCT lumen volume measurements.

Description:

Subjects will be randomized to treatment with either the Chocolate Balloon catheter or a standard balloon angioplasty catheter. All angioplasty procedures will be conducted with treatment balloon at the full discretion of the physician and according to the standard practice at the hospital and the device Instructions for Use. All patients will undergo baseline OCT imaging in addition to standard angiography. Post-PTA, all patients will then undergo repeat OCT imaging immediately post-procedure and then again at 10-minutes post-procedure to assess for vascular recoil.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: March 2015
• Est. primary completion date: March 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Reference Vessel Diameter (RVD) between 2.5 and 6.0mm and within treatment range of available balloon at Target Lesion

• Intermittent claudication or critical limb ischemia (Rutherford 3-5)

• De novo stenosis (=70%) or occlusion in the infrainguinal arteries, including superficial femoral artery (SFA), popliteal, and infrapopliteal arteries.

• Lesion successfully crossed with a guide-wire

• Patient has given informed consent to participate in this study

Exclusion Criteria:

• Lesion requiring ablative procedures (i.e. atherectomy or laser) as part of treatment

• Lesion length >75mm

• Previous bypass or stent at target vessel or proximal to target vessel

• Significant in-flow disease at target lesion

• Known inadequate distal outflow disease or planned treatment of vessel distal to target lesion

• Acute limb ischemia or need for thrombolytic therapy

• Known intolerance to required study medications, contrast media, or nitinol

• Known impaired Renal Function with Glomerular Filtration Rate (GFR) <45 ml/min per 1.73m2

• Known bleeding disorder or uncontrolled hypercoagulable disorder.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Infrainguinal Peripheral Arterial Disease
• Peripheral Arterial Disease
• Peripheral Vascular Diseases

Intervention

Device:
• Chocolate PTA Balloon Angioplasty
OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
• Standard PTA Balloon Angioplasty
OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later

Locations

Country	Name	City	State
United States	Case Medical Center	Cleveland	Ohio
United States	Cleveland Clinic	Cleveland	Ohio

Sponsors (2)

Lead Sponsor	Collaborator
TriReme Medical, LLC	University Hospital Case Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Luminal Gain	Luminal Gain as defined by OCT lumen volume measurements. Luminal gain is assessed as the percentage change comparing pre-treatment and post-treatment volume measurements in cubic centimeters (CC) or millimeters (m3).	Average of 90 minutes	No
Secondary	Dissection	Dissection severity (extension) as defined by both angiographic and OCT metrics.; Dissections occur when the blood goes into the vessel wall instead of staying in the vessel lumen. Dissection severity is determined by a visual review of the angiogram and OCT images by an independent core lab. Dissections are classified as flow-limiting (more severe) vs. non-flow limiting (less severe) based upon the amount of the blood that is flowing into the vessel wall.	Average of 90 minutes	No
Secondary	Hematoma	Presence of intramural hematoma on OCT.; A hematoma can be visually observed on a angiogram and an OCT image. The images will be independently reviewed by a core lab expert who will document if a hematoma is present or not.	Average of 90 minutes	No
Secondary	Optimal PTA	Achievement of Optimal PTA (<30% Diameter stenosis without flow limiting dissection); <30% Diameter stenosis and flow limiting dissections are visual assessments that will be conducted by an independent core lab review. The % diameter stenosis measures the amount of plaque that is in the vessel and a flow-limiting dissection is observed as either present or not present.	Average of 90 minutes	No